Janet Jill  Hopkins net worth and biography

Janet Hopkins Biography and Net Worth

Chief Medical Officer and President of Research & Development of Aura Biosciences

Jill Hopkins is the Chief Medical Officer and President of Research & Development at Aura. Before joining Aura, Jill served as Senior Vice President, Global Head of Ophthalmology and Exploratory Development at Novartis, and Chief Executive Officer of Gyroscope Therapeutics, a Novartis company, where she was responsible for the global ophthalmic pipeline and portfolio of medicines, gene therapy, devices and digital solutions to impact eye disease and reduce visual impairment globally. Previously, Dr. Hopkins spent over a decade at Roche-Genentech in roles of increasing responsibility, most recently as Global Head Ophthalmology Personalized Health Care. Before Roche-Genentech, she spent over 20 years in clinical retinal research and academic practice at the University of Toronto, University of Southern California, and Retina-Vitreous Associates Medical Group. Jill brings over 30 years of cross-sector experience in ophthalmology, spanning clinical care, academia, education, industry, advocacy, and innovation. Dr. Hopkins received her M.D. from McMaster University and completed her Ophthalmology residency at the University of Toronto. She has completed fellowships in Retinal Disease from Moorfields Eye Hospital in London UK and in Visual Electrophysiology from the Universities of Toronto and Ottawa. Dr. Hopkins is board certified in Ophthalmology from the American Board of Ophthalmology and the Royal College of Surgeons Canada.

What is Janet Jill Hopkins' net worth?

The estimated net worth of Janet Jill Hopkins is at least $1.63 million as of November 17th, 2025. Dr. Hopkins owns 252,685 shares of Aura Biosciences stock worth more than $1,629,818 as of December 5th. This net worth evaluation does not reflect any other investments that Dr. Hopkins may own. Learn More about Janet Jill Hopkins' net worth.

How do I contact Janet Jill Hopkins?

The corporate mailing address for Dr. Hopkins and other Aura Biosciences executives is , , . Aura Biosciences can also be reached via phone at 617-500-8864 and via email at [email protected]. Learn More on Janet Jill Hopkins' contact information.

Has Janet Jill Hopkins been buying or selling shares of Aura Biosciences?

During the last ninety days, Janet Jill Hopkins has sold $92,730.78 in Aura Biosciences stock. Most recently, Janet Jill Hopkins sold 17,109 shares of the business's stock in a transaction on Monday, November 17th. The shares were sold at an average price of $5.42, for a transaction totalling $92,730.78. Following the completion of the sale, the insider now directly owns 252,685 shares of the company's stock, valued at $1,369,552.70. Learn More on Janet Jill Hopkins' trading history.

Who are Aura Biosciences' active insiders?

Aura Biosciences' insider roster includes Elisabet de los Pinos (Insider), Amy Elazzouzi (SVP), Anthony Gibney (Insider), Janet Hopkins (Chief Medical Officer and President of Research & Development), David Johnson (Director), Conor Kilroy (Insider), and Mark Plavsic (CTO). Learn More on Aura Biosciences' active insiders.

Are insiders buying or selling shares of Aura Biosciences?

In the last twelve months, Aura Biosciences insiders bought shares 2 times. They purchased a total of 70,000 shares worth more than $343,000.00. In the last twelve months, insiders at the sold shares 13 times. They sold a total of 79,568 shares worth more than $514,201.11. The most recent insider tranaction occured on November, 17th when insider Janet Jill Hopkins sold 17,109 shares worth more than $92,730.78. Insiders at Aura Biosciences own 6.3% of the company. Learn More about insider trades at Aura Biosciences.

Information on this page was last updated on 11/17/2025.

Janet Jill Hopkins Insider Trading History at Aura Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/17/2025Sell17,109$5.42$92,730.78252,685View SEC Filing Icon  
2/18/2025Sell2,534$7.75$19,638.50269,794View SEC Filing Icon  
11/18/2024Sell11,822$9.36$110,653.92151,693View SEC Filing Icon  
See Full Table

Janet Jill Hopkins Buying and Selling Activity at Aura Biosciences

This chart shows Janet Jill Hopkins's buying and selling at Aura Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Aura Biosciences Company Overview

Aura Biosciences logo
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $6.45
Low: $6.21
High: $6.53

50 Day Range

MA: $5.92
Low: $5.35
High: $6.61

2 Week Range

Now: $6.45
Low: $4.34
High: $9.14

Volume

117,755 shs

Average Volume

200,153 shs

Market Capitalization

$409.58 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.44